Alebund Pharmaceuticals Partners with R1 Therapeutics for AP306 Kidney Disease Treatment in Asian Markets

Alebund Pharmaceuticals has entered into a collaboration and license agreement with R1 Therapeutics to advance the development of AP306, a therapeutic candidate targeting kidney diseases. The agreement grants Alebund exclusive rights to develop, manufacture, and commercialize AP306 in specific regions, including China and other Asian markets. This partnership aims to leverage both companies’ expertise in drug development and commercialization.

Under the terms of the agreement, R1 Therapeutics will receive an upfront payment from Alebund Pharmaceuticals along with potential milestone payments based on the achievement of certain developmental, regulatory, and commercial goals. Additionally, R1 Therapeutics is eligible for royalties on net sales of AP306 in the licensed territories. Both companies have expressed intentions to collaborate closely during the development process to address unmet medical needs in kidney disease treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI